SMT201800533T1 - Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi - Google Patents
Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativiInfo
- Publication number
- SMT201800533T1 SMT201800533T1 SM20180533T SMT201800533T SMT201800533T1 SM T201800533 T1 SMT201800533 T1 SM T201800533T1 SM 20180533 T SM20180533 T SM 20180533T SM T201800533 T SMT201800533 T SM T201800533T SM T201800533 T1 SMT201800533 T1 SM T201800533T1
- Authority
- SM
- San Marino
- Prior art keywords
- tudca
- treatment
- neurodegenerative disorders
- tauroursodeoxycholic acid
- tauroursodeoxycholic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13747521.6A EP3016654B2 (en) | 2013-07-01 | 2013-07-01 | Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders |
| PCT/IB2013/055383 WO2015001379A1 (en) | 2013-07-01 | 2013-07-01 | Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201800533T1 true SMT201800533T1 (it) | 2018-11-09 |
Family
ID=48949193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20180533T SMT201800533T1 (it) | 2013-07-01 | 2013-07-01 | Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3016654B2 (it) |
| CN (2) | CN105358147A (it) |
| CY (1) | CY1120835T1 (it) |
| DK (1) | DK3016654T3 (it) |
| ES (1) | ES2691408T3 (it) |
| HR (1) | HRP20181554T1 (it) |
| HU (1) | HUE040027T2 (it) |
| LT (1) | LT3016654T (it) |
| PL (1) | PL3016654T3 (it) |
| PT (1) | PT3016654T (it) |
| RS (1) | RS57763B1 (it) |
| RU (1) | RU2016102092A (it) |
| SI (1) | SI3016654T1 (it) |
| SM (1) | SMT201800533T1 (it) |
| TR (1) | TR201815345T4 (it) |
| WO (1) | WO2015001379A1 (it) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| BR112022011951A2 (pt) * | 2019-12-16 | 2022-09-06 | Amylyx Pharmaceuticals Inc | Tratamento de esclerose lateral amiotrófica e distúrbios relacionados |
| US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| AU2021219072B2 (en) * | 2020-02-13 | 2024-10-03 | Prilenia Neurotherapeutics Ltd. | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent |
| CN112972480A (zh) * | 2021-03-09 | 2021-06-18 | 兆科药业(广州)有限公司 | 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物 |
| US12138272B2 (en) | 2022-05-12 | 2024-11-12 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| CN120659782A (zh) * | 2023-02-15 | 2025-09-16 | 深圳君圣泰生物技术有限公司 | 小檗碱牛磺熊去氧胆酸盐组合物及其方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1770975A (zh) * | 2003-04-02 | 2006-05-10 | 明尼苏达大学评议会 | 提高细胞生存能力的方法 |
| CA2581126A1 (en) * | 2004-09-24 | 2006-04-06 | Rfe Pharma Llc | Carboxy-amido-triazoles for the localized treatment of ocular diseases |
| CA2585471A1 (en) * | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| ES2358089T3 (es) * | 2004-11-01 | 2011-05-05 | Seo Hong Yoo | Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica. |
| JP2008530100A (ja) | 2005-02-10 | 2008-08-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 視覚障害の治療方法 |
| US20110142799A1 (en) | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| EP2422787A1 (en) * | 2010-08-17 | 2012-02-29 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
-
2013
- 2013-07-01 TR TR2018/15345T patent/TR201815345T4/tr unknown
- 2013-07-01 HR HRP20181554TT patent/HRP20181554T1/hr unknown
- 2013-07-01 PT PT13747521T patent/PT3016654T/pt unknown
- 2013-07-01 SI SI201331212T patent/SI3016654T1/sl unknown
- 2013-07-01 HU HUE13747521A patent/HUE040027T2/hu unknown
- 2013-07-01 RU RU2016102092A patent/RU2016102092A/ru unknown
- 2013-07-01 EP EP13747521.6A patent/EP3016654B2/en active Active
- 2013-07-01 DK DK13747521.6T patent/DK3016654T3/en active
- 2013-07-01 LT LTEP13747521.6T patent/LT3016654T/lt unknown
- 2013-07-01 PL PL13747521T patent/PL3016654T3/pl unknown
- 2013-07-01 CN CN201380077879.3A patent/CN105358147A/zh active Pending
- 2013-07-01 SM SM20180533T patent/SMT201800533T1/it unknown
- 2013-07-01 CN CN201910097334.8A patent/CN109999030A/zh active Pending
- 2013-07-01 ES ES13747521.6T patent/ES2691408T3/es active Active
- 2013-07-01 RS RS20181232A patent/RS57763B1/sr unknown
- 2013-07-01 WO PCT/IB2013/055383 patent/WO2015001379A1/en not_active Ceased
-
2018
- 2018-10-17 CY CY181101065T patent/CY1120835T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015001379A1 (en) | 2015-01-08 |
| RS57763B1 (sr) | 2018-12-31 |
| CN109999030A (zh) | 2019-07-12 |
| DK3016654T3 (en) | 2018-11-05 |
| EP3016654B1 (en) | 2018-09-05 |
| LT3016654T (lt) | 2018-11-12 |
| CN105358147A (zh) | 2016-02-24 |
| TR201815345T4 (tr) | 2018-11-21 |
| CY1120835T1 (el) | 2019-12-11 |
| PL3016654T3 (pl) | 2019-02-28 |
| HRP20181554T1 (hr) | 2018-12-14 |
| PT3016654T (pt) | 2018-11-09 |
| SI3016654T1 (sl) | 2019-05-31 |
| EP3016654A1 (en) | 2016-05-11 |
| EP3016654B2 (en) | 2025-11-12 |
| HUE040027T2 (hu) | 2019-02-28 |
| ES2691408T3 (es) | 2018-11-27 |
| RU2016102092A (ru) | 2017-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273815B (en) | Secondary vaccine particles for the treatment of inflammation | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| SMT202000346T1 (it) | 19-norsteroidi neuroattivi per metodi di trattamento | |
| SG10201912275YA (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders | |
| EP3068492A4 (en) | Neurodegenerative disorders and methods of treatment and diagnosis thereof | |
| IL241191A0 (en) | Local compositions and methods for treating local disorders | |
| PL2838539T3 (pl) | Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych | |
| SMT201800533T1 (it) | Acido tauroursodesossicolico (tudca) per l'uso nel trattamento dei disturbi neurodegenerativi | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| EP3038707A4 (en) | Treatment of pediatric otic disorders | |
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| EP2941252A4 (en) | USE OF FATTY ACID NIACIN CONJUGATES FOR THE TREATMENT OF DISEASES | |
| EP3013824B8 (en) | Carboline compounds usable in the treatment of neurodegenerative diseases | |
| ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
| IL236993A0 (en) | A liquid substance to administer for the treatment of dermatophytosis | |
| ZA201507724B (en) | The treatment of inflammatory disorders | |
| EP2958570A4 (en) | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS | |
| HUE058845T2 (hu) | Nem biokonvertibilis C3-szubsztituált pregnenolon-származékok szerhasználati zavarok kezelésében történõ alkalmazásra | |
| HUE045296T2 (hu) | Epesavat tartalmazó gyermekgyógyászati készítmény | |
| IL245613B (en) | Peptides for use in the treatment of inflammatory diseases that are not related to pathogenic factors | |
| AU2013901514A0 (en) | Formulation and methods for treatment of mental disorders | |
| GB201308539D0 (en) | Liquid treatment | |
| GB201310590D0 (en) | Wheelchair with various assistance elements |